Nomir Heading


Fungal infections represent a $4.0 billion market, including $1.5 billion for onychomycosis (OM, or toe nail fungus) (i). Approximately 35 million people in the United States, and 700 million worldwide (i), suffer from OM. However, many of these patients, as well as the clinicians who treat them, are left with few or no treatment options due to the safety concerns associated with the current standard of treatment, systemic pharmaceutical antifungal therapy.

(i) UpToDate, Ferri’s Clinical Advisor 2008